Genmab A/S (GMAB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 28.75 |
| Open | 28.27 |
| Bid | 27.68 x 200 |
| Ask | 27.74 x 200 |
| Day's Range | 27.42 - 28.27 |
| 52 Week Range | 26.32 - 42.72 |
| Volume | |
| Avg. Volume | 564,598 |
| Market Cap | 17.924B |
| Beta (5Y Monthly) | 0.78 |
| PE Ratio (TTM) | 29.18 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GuruFocus.com
Comstock Inc (LODE) Q1 2024 Earnings Call Transcript Highlights: Strategic Investments and ...
Explore key insights from Comstock Inc's Q1 2024 earnings, including significant revenue streams, strategic investments, and future financial strategies.
- Investor's Business Daily
Genmab Takes The Next Step In Its 'Evolution' With A $1.8 Billion Takeover
Genmab stock slumped Wednesday after the Danish biotech announced it will buy privately held ProfoundBio for $1.8 billion.
- Reuters
Denmark's Genmab to acquire ProfoundBio for $1.8 billion
The acquisition will give Genmab worldwide rights to three candidates in clinical development, they said. Genmab shares were down 1.7% at 0955 GMT. Jyske bank analyst Henrik Hallengreen Laustsen said that while the acquisition is seen as slightly positive for Genmab shares, the price is difficult to assess, and added it might be "a bit high".
© 2024 Yahoo. All rights reserved.